Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers-Reference-Cited by-同舟云学术

Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers

Published:2024-03 Issue:3 Volume:49 Page:102229
ISSN:0146-2806
Container-title:Current Problems in Cardiology
language:en
Short-container-title:Current Problems in Cardiology

Author:

Di Lisi Daniela^ORCID,Cadeddu Dessalvi Christian,Zito Concetta,Madaudo Cristina,Manganaro Roberta,Mercurio Valentina,Deidda Martino,Santoro Ciro,Penna Claudia,Monte Ines Paola,Spallarossa Paolo,Tocchetti Carlo Gabriele,Novo Giuseppina

Funder

Ministero della Salute

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference61 articles.

1. Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist;Bonura;Cardiovasc Toxicol,2012

2. Redox imbalances in ageing and metabolic alterations: implications in cancer and cardiac diseases. an overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC);Mercurio;Antioxidants (Basel).,2020

3. Cancer Therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging;Bloom;Circ Heart Fail,2016

4. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives;Bair;Trends Cardiovasc Med,2013

5. Risk of arterial thrombo- embolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials;Choueiri;J Clin Oncol,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review regarding the article ‘The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction—A systematic review’;Current Problems in Cardiology;2024-05